Work

Clinical Evaluation of Adriamycin, a New Antitumour Antibiotic

Year: 1969

Type: article

Abstract: Adriamycin, a new antitumour antibiotic of the anthracycline group with a structural formula very similar to daunorubicin, has proved to have potent tumour-growth-inhibiting properties, and to be particularly effective in childhood malignancies. Though adriamycin produces a higher percentage of side-effects than daunorubicin-namely, stomatitis and alopecia-a lower dosage may be used for therapy.

Source: BMJ

DOI: 10.1136/bmj.3.5669.503

Authors: Gianni Bonadonna, Silvio Monfardini, Mario de Lena, Franca Fossati-Bellani

Institutions: Fondazione IRCCS Istituto Nazionale dei Tumori, Don Carlo Gnocchi Foundation

Language: English

Topic: Cancer therapeutics and mechanisms

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

Funder: National Cancer Institute